Elixir Medical Corporation Patent applications |
Patent application number | Title | Published |
20150025619 | BIODEGRADABLE ENDOPROSTHESES AND METHODS FOR THEIR FABRICATION - The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature in a body lumen from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen. | 01-22-2015 |
20140350659 | BIODEGRADABLE ENDOPROSTHESES AND METHODS FOR THEIR FABRICATION - Biodegradable endoprostheses are formed from amorphous polymers having desirable biodegradation characteristics. The strength of such amorphous polymers is enhanced by annealing to increase crystallinity without substantially increasing the biodegradation time. | 11-27-2014 |
20140188243 | BIODEGRADABLE ENDOPROSTHESES AND METHODS FOR THEIR FABRICATION - The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen. | 07-03-2014 |
20130331927 | BIODEGRADABLE ENDOPROSTHESIS AND METHODS FOR THEIR FABRICATION - The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature in a body lumen from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen. | 12-12-2013 |
20130230571 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present disclosure provides a device for intracorporeal use which comprises an implant or a temporary device and at least one source of myolimus or a derivative thereof. The present disclosure also provides a method of inhibiting cell proliferation, inflammation or cytokine production by systemic or local administration of a therapeutically effective amount of myolimus or a derivative thereof. Further included in the present disclosure is a method of treating an ophthalmic condition or disease by administering a therapeutically effective amount of myolimus or a derivative thereof. | 09-05-2013 |
20130150943 | BIODEGRADABLE ENDOPROSTHESES AND METHODS FOR THEIR FABRICATION - The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen. | 06-13-2013 |
20120271396 | BIODEGRADABLE ENDOPROSTHESES AND METHODS FOR THEIR FABRICATION - The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen. | 10-25-2012 |
20120226345 | BIODEGRADABLE ENDOPROSTHESES AND METHODS FOR THEIR FABRICATION - Biodegradable endoprostheses are formed from amorphous polymers having desirable biodegradation characteristics. The strength of such amorphous polymers is enhanced by annealing to increase crystallinity without substantially increasing the biodegradation time. | 09-06-2012 |
20120187606 | BIODEGRADABLE ENDOPROSTHESES AND METHODS FOR THEIR FABRICATION - Biodegradable endoprostheses are formed from amorphous polymers having desirable biodegradation characteristics. The strength of such amorphous polymers is enhanced by annealing to increase crystallinity without substantially increasing the biodegradation time. | 07-26-2012 |
20120094932 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: | 04-19-2012 |
20120093891 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: | 04-19-2012 |
20120071962 | INTRAVASCULAR STENT - Stents are provided with scaffold structures which have low exposures when implanted in arteries and other blood vessels and lumens. The cross-sectional dimensions, materials, and patterns are controlled to provide sufficient strength and coverage while maintaining the low exposure. | 03-22-2012 |
20120071500 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: | 03-22-2012 |
20110097364 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: | 04-28-2011 |
20100086579 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a device for intracorporeal use including an implant or a temporary device and at least one source of a compound myolimus, or a derivative thereof. The present invention also provides a method of inhibiting cell proliferation by local administration of a therapeutically effective amount of a compound myolimus, or a derivative thereof. Further included in the present invention is a method of treating an ophthalmic condition or disease by administering a therapeutically effective amount of a compound myolimus, or a derivative thereof. | 04-08-2010 |
20080234309 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: | 09-25-2008 |